SSB
CBAY

Sandy Spring Bank’s Cymabay Therapeutics CBAY Stock Holding History

Sandy Spring Bank’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-1,325
Closed -$8K – 855
2017
Q2 		$8K Buy
+1,325
New +$5.64K ﹤0.01% 718

Other funds holding CBAY

Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
A
Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Sandy Spring Bank's CBAY Position: Q3 2017 in Review

Sandy Spring Bank sold out of Cymabay Therapeutics (CBAY) in Q3 2017, closing a stake of 1,325 shares — an estimated $8K sold.

Sandy Spring Bank first reported a position in CBAY in Q2 2017 and held it in 1 quarter. The position peaked at $8K in Q2 2017. 64 funds tracked by Wall St. Rank hold CBAY as of Q3 2017.

  • Sandy Spring Bank reported no remaining Cymabay Therapeutics position as of Q3 2017 after selling out during the quarter.
  • Sandy Spring Bank sold 1,325 Cymabay Therapeutics shares in Q3 2017, an estimated $8K.
  • Sandy Spring Bank first reported a position in Cymabay Therapeutics in Q2 2017 and held it in 1 quarter.
  • Sandy Spring Bank's Cymabay Therapeutics position peaked at $8K in Q2 2017.
  • 64 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q3 2017.

Based on Sandy Spring Bank's 13F filing for Q3 2017, filed 3 Nov 2017.